Method for production of alpha emitter Tb by irradiation of Eu with 70 MeV He nuclei is proposed. For the first time, the cross sections for the formation of isotopes Tb were measured experimentally using a stack foil technique in the He particles energy range 70 → 12 MeV. The thick target yield of Tb is 39 MBq/μAh, or 230 MBq/μA Tb at saturation. The optimal energy range from the point of view of radioisotopic purity is 70 → 40 MeV. At these conditions about 150 MBq/μA Tb can be produced in 8 hours irradiation, which is sufficient for therapeutic applications. The main impurities are Tb (~100% in activity) and Tb (~30% in activity). The proposed method surpasses its counterparts by the high content of the target isotope in the natural mixture and the simplicity of the radiochemical separation of Tb from the bulk target material.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965643 | PMC |
| http://dx.doi.org/10.1038/s41598-020-57436-6 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Millimeter-scale radioluminescent power for electronic sensors.
iScience
January 2025
Department of Electrical Engineering and Computer Sciences, University of California, Berkeley, Berkeley, CA 94720, USA.
The storage and generation of electrical energy at the mm-scale is a core roadblock to realizing many untethered miniature systems, including industrial, environmental, and medically implanted sensors. We describe the potential to address the sensor energy requirement in a two-step process by first converting alpha radiation into light, which can then be translated into electrical power through a photovoltaic harvester circuit protected by a clear sealant. Different phosphorescent and scintillating materials were mixed with the alpha-emitter Th-227, and the conversion efficiency of europium-doped yttrium oxide was the highest at around 2%.
View Article and Find Full Text PDFModeling absorbed alpha particle dose from diffusing alpha-emitters radiation therapy in changing tissue volumes.
Med Phys
January 2025
Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Background: Diffusing alpha-emitters Radiation Therapy ("Alpha DaRT") is a promising new radiation therapy modality for treating bulky tumors. Ra-carrying sources are inserted intratumorally, producing a therapeutic alpha-dose region with a total size of a few millimeter via the diffusive motion of Ra's alpha-emitting daughters. Clinical studies of Alpha DaRT have reported 100% positive response (30%-100% shrinkage within several weeks), with post-insertion swelling in close to half of the cases.
View Article and Find Full Text PDFCross sections of the Ra(p,xn) reactions relevant for Ac production.
Nucl Med Biol
January 2025
Nuclear Physics Institute of the Czech Academy of Sciences, Řež, Czech Republic.
Limited availability constrains the implementation of Ac, the most promising α emitter for targeted therapy, in clinical practice. Proton activation of Ra is one of few realistic solutions to this problem. We have therefore measured cross sections of relevant Ra(p,xn) nuclear reactions in the energy range of 12.
View Article and Find Full Text PDFRapid fabrication and dissolution of pressed Ni/Mg matrix targets for Co production.
EJNMMI Radiopharm Chem
January 2025
Department of Nuclear Medicine and Medical Physics, Karolinska University Hospital, Stockholm, 171 76, Sweden.
Background: Beyond the use of conventional short-lived PET radionuclides, there is a growing interest in tracking larger biomolecules and exploring radiotheranostic applications. One promising option for imaging medium-sized molecules and peptides is ⁵⁵Co (T₁/₂ = 17.5 h, β⁺ = 76%), which enables imaging of new and already established tracers with blood circulation of several hours.
View Article and Find Full Text PDFAlpha Atlas: Mapping global production of α-emitting radionuclides for targeted alpha therapy.
Nucl Med Biol
December 2024
Life Sciences Division, TRIUMF, BC V6T 2A3 Vancouver, British Columbia, Canada; Department of Chemistry, University of British Columbia, V6T 1Z1 Vancouver, British Columbia, Canada.
Targeted Alpha Therapy has shown great promise in cancer treatment, sparking significant interest over recent decades. However, its broad adoption has been impeded by the scarcity of alpha-emitters and the complexities related to their use. The availability of these radionuclides is often constrained by the intricate production processes and purification, as well as regulatory and logistical challenges.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!